At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SBP GROUP
Trading 09-18 13:33:08
5.550
+0.055
+1.00%
High5.680Low5.445Vol45.95M
Open5.525D1 Closing5.495Amplitude4.28%
Mkt Cap103.69BTradable Cap103.69BTotal Shares18.68B
T/O254.32MT/O Rate0.25%Tradable Shares18.68B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜SBP GROUP Rises 3.18% in Regular Trading, Dual NDA Acceptances and CT Tianqing Stake Increase Completion Fuel Gains
Market Focus  ·  09:59
Movement Alert｜SBP GROUP Rises 3.18% in Regular Trading, Dual NDA Acceptances and CT Tianqing Stake Increase Completion Fuel Gains
Hong Kong Stocks in Focus: SBP Group Jumps Nearly 3% on Double New Drug Approval Submissions
Stock News  ·  09-16 10:36
Hong Kong Stocks in Focus: SBP Group Jumps Nearly 3% on Double New Drug Approval Submissions
Sino Biopharmaceutical Says China's CDE Accepts NDA for Tqh2722 Injection
Reuters  ·  09-16 09:53
Sino Biopharmaceutical Says China's CDE Accepts NDA for Tqh2722 Injection
Hong Kong Market Open: Hang Seng Index Rises 0.50% as Optics Stocks Rally, CATL Slides Over 2%
Stock News  ·  09-16 09:53
Hong Kong Market Open: Hang Seng Index Rises 0.50% as Optics Stocks Rally, CATL Slides Over 2%
Chinese Regulator Accepts NDA for Sino Biopharm's Breast Cancer Drug
MT Newswires Live  ·  09-16 09:35
Chinese Regulator Accepts NDA for Sino Biopharm's Breast Cancer Drug
Sino Biopharm (SBP Group) Receives CDE Acceptance of NDA for IL-4Rα Monoclonal Antibody TQH2722 Targeting Moderate-to-Severe Atopic Dermatitis
Bulletin Express  ·  09-16 07:23
Sino Biopharm (SBP Group) Receives CDE Acceptance of NDA for IL-4Rα Monoclonal Antibody TQH2722 Targeting Moderate-to-Severe Atopic Dermatitis
China Biopharmaceuticals Advances Novel HER2-Targeting Bispecific ADC Toward Market Approval
Stock News  ·  09-16 07:16
China Biopharmaceuticals Advances Novel HER2-Targeting Bispecific ADC Toward Market Approval
Sino Biopharmaceutical - China Cde Accepts New Drug Application for Tqb2102 Injection
THOMSON REUTERS  ·  09-16 07:04
Sino Biopharmaceutical - China Cde Accepts New Drug Application for Tqb2102 Injection
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong
Dow Jones  ·  09-15 16:33
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong
Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors
Dow Jones  ·  09-14
Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors
Big Pharma is Pouring Billions into China's Biotechs
Dow Jones  ·  09-14
Big Pharma is Pouring Billions into China's Biotechs
Sino Biopharmaceutical Climbs on Plan to Raise Stake in Core Unit
Reuters  ·  09-14
Sino Biopharmaceutical Climbs on Plan to Raise Stake in Core Unit
Goldman Sachs Lifts SBP Group Target Price to HK$9.07, Reaffirms Buy Rating
Stock News  ·  09-14
Goldman Sachs Lifts SBP Group Target Price to HK$9.07, Reaffirms Buy Rating
HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback
Stock News  ·  09-14
HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback
Movement Alert｜SBP GROUP Rises 3.14% in Regular Trading, Plans RMB 4.48 Billion Acquisition to Raise CT Tianqing Stake to 65%
Market Focus  ·  09-14
Movement Alert｜SBP GROUP Rises 3.14% in Regular Trading, Plans RMB 4.48 Billion Acquisition to Raise CT Tianqing Stake to 65%
Movement Alert｜SBP GROUP Rises 3.43% at Open, Plans RMB 4.48 Billion Acquisition to Boost CT Tianqing Stake to 65%
Market Focus  ·  09-14
Movement Alert｜SBP GROUP Rises 3.43% at Open, Plans RMB 4.48 Billion Acquisition to Boost CT Tianqing Stake to 65%
Biopharma Giant's HK$4.48 Billion Stake Purchase Highlights Key Hong Kong Stock Market Announcements
Stock News  ·  09-14
Biopharma Giant's HK$4.48 Billion Stake Purchase Highlights Key Hong Kong Stock Market Announcements
Crude Supply Shock Looms as Saudi Pipeline Outage Threatens 4% of Global Output
Stock News  ·  09-14
Crude Supply Shock Looms as Saudi Pipeline Outage Threatens 4% of Global Output
Sino Biopharm Secures Deal to Up Stake in CT Tianqing
MT Newswires Live  ·  09-11
Sino Biopharm Secures Deal to Up Stake in CT Tianqing
Sino Biopharmaceutical - Sbp Group to Buy 5% Equity Interest in Ct Tianqing for Rmb4.48 Bln at 19X Ltm P/E
THOMSON REUTERS  ·  09-11
Sino Biopharmaceutical - Sbp Group to Buy 5% Equity Interest in Ct Tianqing for Rmb4.48 Bln at 19X Ltm P/E

Introduction

Company Name.
SBP GROUP
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
Issue price:
--